Revance Therapeutics (RVNC) reported positive results Tuesday from a pair of late-stage clinical trials of its longer-lasting version of a Botox-like wrinkle reducer. The product, if approved, aims to take on market leader Allergan.
The Revance product, known as RT002, is an injectable form of botulinum toxin formulated to last for six months. The company has pitched RT002 as a “better” Botox, which is also injected but is generally durable for three to four months.
About the Author Reprints
